Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380447029> ?p ?o ?g. }
- W4380447029 endingPage "035001" @default.
- W4380447029 startingPage "035001" @default.
- W4380447029 abstract "Abstract In this study, the immunostimulatory and anticancer activities of the doxorubicin (DOX), MCF-7 and MDA-MB-231 breast cancer antigen-loaded polycaprolactone (PCL) nanoparticles (NPs) in combination with survivin recombinant protein (RP) and an alum adjuvant are evaluated in vitro on J774 macrophage, MCF-7 and MDA-MB-231 breast cancer cell lines. A double-emulsion solvent evaporation method was used for encapsulation of DOX and antigens into PCL NPs. The physicochemical characterization of NPs included size, morphology, zeta potential, release profiles and encapsulation efficiencies, analyzed using scanning electron microscopy, a zeta-sizer and UV–vis spectrometry. The cytotoxic and inhibitory effects of NPs were determined using a methyl thiazolyl tetrazolium assay. Immunostimulatory effects of the NPs were detected by Griess reaction and ELISA tests to determine nitric oxide and cytokine levels, respectively. According to the results, DOX and antigen-loaded PCL NPs ranged between 240 nm and 290 nm. Antigen and drug-loaded NPs appear less toxic over macrophage cells in comparison with non-capsulated free agents. In addition, considerable inhibitory effects of antigen and drug-loaded NPs were observed at non-toxic concentrations, such as 25 and 50 μ g ml −1 , on human mammary cancer cell lines ( p ⩽ 0.0001). The amount of nitrite released from macrophages that were treated with antigen and DOX-encapsulated PCL NPs, in combination with alum and survivin RP, after 96 h incubation was significantly higher than the control, especially at 50 and 100 μ g ml −1 , and triggered macrophages to produce high quantities of IL-4 and IL-12 cytokines in contrast to the control. As a result, DOX and antigen-loaded PCL NPs in combination with survivin and alum adjuvant revealed significant immunostimulatory and inhibiting influence on macrophage and breast cancer cells, respectively. The outcomes revealed that antigen and drug-loaded PCL NPs supplemented with survivin RP and an alum adjuvant created an effective platform for the development of nanotechnology-based immunotherapeutic tools to inhibit breast cancer cells. However, these outputs should be supported by further in vivo studies." @default.
- W4380447029 created "2023-06-14" @default.
- W4380447029 creator A5010376782 @default.
- W4380447029 creator A5065338614 @default.
- W4380447029 creator A5072467026 @default.
- W4380447029 creator A5074314597 @default.
- W4380447029 creator A5086644257 @default.
- W4380447029 creator A5090063999 @default.
- W4380447029 creator A5092151666 @default.
- W4380447029 creator A5092151667 @default.
- W4380447029 date "2023-07-06" @default.
- W4380447029 modified "2023-10-17" @default.
- W4380447029 title "Evaluation of in vitro immunostimulatory and cytotoxic effects of recombinant survivin protein in combination with doxorubicin and breast cancer antigen-loaded polycaprolactone nanoparticles" @default.
- W4380447029 cites W1602732985 @default.
- W4380447029 cites W1780836844 @default.
- W4380447029 cites W1983682342 @default.
- W4380447029 cites W1996753689 @default.
- W4380447029 cites W2012734571 @default.
- W4380447029 cites W2026523347 @default.
- W4380447029 cites W2032346949 @default.
- W4380447029 cites W2042662562 @default.
- W4380447029 cites W2055069783 @default.
- W4380447029 cites W2058429395 @default.
- W4380447029 cites W2062197511 @default.
- W4380447029 cites W2082480920 @default.
- W4380447029 cites W2082803022 @default.
- W4380447029 cites W2110378444 @default.
- W4380447029 cites W2171834331 @default.
- W4380447029 cites W2586464879 @default.
- W4380447029 cites W2626116039 @default.
- W4380447029 cites W2780248792 @default.
- W4380447029 cites W2792242565 @default.
- W4380447029 cites W2804447831 @default.
- W4380447029 cites W2887204739 @default.
- W4380447029 cites W2889344199 @default.
- W4380447029 cites W2893938412 @default.
- W4380447029 cites W2905111869 @default.
- W4380447029 cites W2905928689 @default.
- W4380447029 cites W2908402498 @default.
- W4380447029 cites W2925395230 @default.
- W4380447029 cites W2936820838 @default.
- W4380447029 cites W2937988520 @default.
- W4380447029 cites W2945530495 @default.
- W4380447029 cites W2969272216 @default.
- W4380447029 cites W2969830238 @default.
- W4380447029 cites W3005609359 @default.
- W4380447029 cites W3011990170 @default.
- W4380447029 cites W3025323602 @default.
- W4380447029 cites W3026936970 @default.
- W4380447029 cites W3092842569 @default.
- W4380447029 cites W3096340664 @default.
- W4380447029 cites W3097577006 @default.
- W4380447029 cites W3109175864 @default.
- W4380447029 cites W3111948762 @default.
- W4380447029 cites W3127469402 @default.
- W4380447029 cites W3134600054 @default.
- W4380447029 cites W3171846279 @default.
- W4380447029 cites W3191429002 @default.
- W4380447029 cites W3197616399 @default.
- W4380447029 cites W4224244538 @default.
- W4380447029 cites W4255349794 @default.
- W4380447029 cites W4281251857 @default.
- W4380447029 cites W4281713224 @default.
- W4380447029 cites W4283770625 @default.
- W4380447029 cites W4290760080 @default.
- W4380447029 cites W4296037048 @default.
- W4380447029 cites W4297855531 @default.
- W4380447029 cites W4300690596 @default.
- W4380447029 cites W4304758886 @default.
- W4380447029 cites W4324149149 @default.
- W4380447029 cites W619024913 @default.
- W4380447029 doi "https://doi.org/10.1088/2399-1984/acde26" @default.
- W4380447029 hasPublicationYear "2023" @default.
- W4380447029 type Work @default.
- W4380447029 citedByCount "0" @default.
- W4380447029 crossrefType "journal-article" @default.
- W4380447029 hasAuthorship W4380447029A5010376782 @default.
- W4380447029 hasAuthorship W4380447029A5065338614 @default.
- W4380447029 hasAuthorship W4380447029A5072467026 @default.
- W4380447029 hasAuthorship W4380447029A5074314597 @default.
- W4380447029 hasAuthorship W4380447029A5086644257 @default.
- W4380447029 hasAuthorship W4380447029A5090063999 @default.
- W4380447029 hasAuthorship W4380447029A5092151666 @default.
- W4380447029 hasAuthorship W4380447029A5092151667 @default.
- W4380447029 hasConcept C109316439 @default.
- W4380447029 hasConcept C141071460 @default.
- W4380447029 hasConcept C147483822 @default.
- W4380447029 hasConcept C153911025 @default.
- W4380447029 hasConcept C154317977 @default.
- W4380447029 hasConcept C178790620 @default.
- W4380447029 hasConcept C185592680 @default.
- W4380447029 hasConcept C190283241 @default.
- W4380447029 hasConcept C202751555 @default.
- W4380447029 hasConcept C203014093 @default.
- W4380447029 hasConcept C2775975398 @default.
- W4380447029 hasConcept C2776694085 @default.
- W4380447029 hasConcept C2777863537 @default.
- W4380447029 hasConcept C2779868350 @default.